ArticleBMJ open respiratory research2026
Predictive ability of the COPD-specific comorbidity test (COTE) score versus the Charlson comorbidity index (CCI) in patients with COPD.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe chronic obstructive pulmonary disease (COPD)-specific comorbidity test (COTE) aims to predict long-term mortality in patients with COPD, whereas the Charlson comorbidity index (CCI) score is used as a validated tool for predicting long-term mortality across medical conditions. Comparison of the two comorbidity scores' ability to predict mortality has only been studied scarcely. AIMS AND
objectivesThis study aimed to compare the predictive ability of the COTE and CCI scores including the updated CCI score with updated weights (CCI (Quan)) in patients with COPD following acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
methodsUsing nationwide registry data, all Danish patients at first admission due to AECOPD during 2005-2018 were included in this retrospective cohort study. 1-year mortality was explored including age, sex and CCI or COTE comorbidity scores. Logistic regression was performed with fivefold cross-validation comparing area under the curve (AUC) and optimal threshold using Youden index. The logistic regression models were furthermore examined using 10 000 bootstrap analyses and comparing the distribution of accuracy using a T-test. Cox regression analysis was used to compare Brier scores over time for models including combinations of age, sex, COTE, CCI and CCI (Quan).
resultsA total of 87 271 individuals were identified with a first-time AECOPD during the study period. The median age was 74 IQR (66, 81) and 48.4% were males.The logistic regression revealed an AUC of the CCI and CCI (Quan) models of 0.714 and for the COTE model 0.707 (p<0.001).Comparison using T-test on 10 000 bootstrap samples revealed small differences with an accuracy of 0.7281 (95% CI 0.7241 to 0.7320) for the COTE model and 0.7275 (95% CI 0.7235 to 7314) for the CCI model (p<0.001).Brier scores were 0.1793 for CCI, 0.1789 for CCI (Quan) and 0.1802 for COTE, only slightly favouring the CCI model.
conclusionsIn a cohort of patients with first-time AECOPD, we found similar predictive abilities of 1-year mortality comparing the CCI, CCI (Quan) and COTE score.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.